Amirali Talasaz Sells Guardant Health Shares
Co-CEO Amirali Talasaz sold shares of Guardant Health on June 26, 2026.
Key Points
- Amirali Talasaz, Co-CEO of Guardant Health, sold shares on June 26, 2026, with shares trading near $153.74 on Wednesday.
- Guardant Health has a market cap of about $19.8 billion, a forward P/E of -380.8, and a 52-week range of $40.35 to $151.85.
- Analysts maintain a strong buy consensus with a mean price target of $144.42, highlighting recent positive sentiment.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 26, 2026, Amirali Talasaz, Co-Chief Executive Officer of Guardant Health, Inc. (NasdaqGS: GH), sold shares of the company. This transaction occurred as shares of the company traded near $153.74 on Wednesday.
Insider Buying and Selling at Guardant Health, Inc.
Amirali Talasaz, the Co-CEO of Guardant Health, sold shares on June 26, 2026. This transaction was not part of a pre-planned trading strategy. On the same day, Talasaz also made additional trades, including purchases and sales, under different conditions.
Other Institutional Activity in Guardant Health
BlackRock, Inc. increased its holdings in Guardant Health by 236,045 shares, bringing its total to 11,553,759 shares valued at approximately $1.07 billion, marking a 2.1% increase. Price T Rowe Associates added 1,387,611 shares, boosting its stake by 24.6% to 7,023,689 shares worth about $648.8 million. Vanguard Portfolio Management LLC and Vanguard Capital Management LLC both opened new positions, acquiring 5,837,992 and 5,624,180 shares respectively. In contrast, Invesco Ltd. reduced its holdings by 369,465 shares, a 7.0% decrease, resulting in 4,946,469 shares valued at $456.9 million.
Guardant Health, Inc. Stock Down 3.3%
Shares of Guardant Health traded near $153.74 on Wednesday. The company has a market capitalization of approximately $19.8 billion and a forward P/E ratio of -380.8, indicating it is not currently profitable. Guardant Health's stock has a 52-week low of $40.35 and a high of $151.85. The stock's 50-day moving average is $111.18, and the 200-day moving average is $95.82. The company's current ratio is 4.68, and its quick ratio is 4.25, reflecting strong liquidity.
$GH stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
Guardant Health reported revenue of $1.08 billion, with a growth rate of 48.3%. However, the company posted a net margin of -40.1%, indicating it is operating at a loss. The next earnings report is expected on July 29, 2026.
Analysts Set New Price Targets
On June 29, 2026, Guggenheim maintained its buy rating on Guardant Health with a price target of $160. Bernstein reinstated its buy rating with a $175 target on June 26, 2026. Barclays maintained its buy rating with a $150 target on June 24, 2026. The consensus among analysts is a strong buy, with an average price target of $144.42 based on 24 opinions.
About Guardant Health
Guardant Health, Inc. is a healthcare company specializing in precision oncology. Headquartered in Palo Alto, California, the company develops blood and tissue tests aimed at advancing cancer research and treatment. Its products include the Guardant360 CDx test for tumor mutation profiling and the Guardant Reveal test for early cancer detection. The company is led by CEO Dr. Helmy Eltoukhy and employs approximately 2,490 people.
Bottom Line
Amirali Talasaz's recent share sale is part of ongoing insider activity at Guardant Health. The company continues to attract institutional interest, with notable changes in holdings by major funds. Analysts remain optimistic about the stock, maintaining a strong buy consensus. As always, it's important to remember that insider transactions and institutional filings provide a historical snapshot and may not reflect the current position or sentiment.
Get Guardant Health, Inc. alerts
New 13F filings, insider trades, and analyst moves on $GH, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.